Optimal intensity of oral anticoagulant therapy after myocardial infarction

Journal of the American College of Cardiology

Volumn 27, Issue 6, 1996, Pages 1349-1355

  Azar, Aida J ^a,b   Cannegieter, Suzanne C ^c   Deckers, Jaap W ^a   Briët, Ernest ^c   Van Bergen, Paul F M M ^b   Jonker, Jan J C ^b   Rosendaal, Frits R ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ASPECT Coordinating Centre   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; PHENPROCOUMON; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0030002332     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00020-4     Document Type: Article

References (27)

1. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-93.
2. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
3. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;1:499-503.
4. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemostas 1993;69:236-39.
5. Azar AJ, Deckers JW, Rosendaal FR, et al. Assessment of therapeutic achievement in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Hemostas 1994;72:347-51.
6. Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol (Basel) 1985;74: 125-31.
7. Loeliger EA, Broekmans AW. Optimal therapeutic anticoagulation. Haemostasis 1985;15:283-92.
8. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemostas 1985;53:155-6.
9. Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and proposal. Thromb Haemostas 1979;42:1141-52.
10. Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959;2:754-8.
11. The Ad Hoc Committee on the Classification and Outline of Cerebrovascular Disease. II (Chairman Milikan CH). Stroke 1975;6:566-616.
12. The Criteria Committee of the New York Heart Association. Disease of the Heart and Blood Vessels; Nomenclature and Criteria for Diagnosis, 7th ed. Boston: Little, Brown, 1973.
13. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 8th ed. Boston: Little, Brown, 1979.
14. Greenberg RS, Kleinbaum DG. Mathematical modeling strategies for the analysis of epidemiologic research. Annu Rev Public Health 1985;6:223-45.
15. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-81.
16. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-94.
17. Turpie AGG, Hirsh J, Gunstensen J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-5.
18. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-32.
19. Forfar JC. A 7-year analysis of hemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979:42:128-32.
20. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989;87:153-9.
21. Petiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhages. Am J Med 1986;81:255-9.
22. Second report of the Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982;1:64-8.
23. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993;153:1557-62.
24. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991;229:351-5.
25. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988;148:1733-6.
26. Hirsh J, Levine M. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America. Thromb Haemostas 1988;59:129-32.
27. Loeliger EA. Therapeutic target values in oral anticoagulation - justification of Dutch policy and a warning against the so-called moderate-intensity regimens. Ann Hematol 1992;64:60-5.